120 results match your criteria: "Medical Data Analytics Centre[Affiliation]"

Purpose: Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1-antihistamine use is associated with improved overall survival in patients with lung and skin cancers receiving immunotherapy. Therefore, we retrospectively evaluated the impacts of H1-antihistamine use in cancer patients during immunotherapy.

View Article and Find Full Text PDF

Background: The older population is more vulnerable to the impact of extreme hot weather events (EHWEs), while the impact on the frailer institutionalised older population was seldom assessed. Our objective was to assess the relationship between EHWEs and hospitalisation risks among institutionalised and community-dwelling older people.

Methods: We used territory-wide hospitalisation record of Hong Kong from year 2012 to 2018 to assess the associations between EHWEs and cardiovascular and respiratory disease hospitalisations in the population aged 65 or above.

View Article and Find Full Text PDF

Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study).

J Hepatol

August 2024

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada. Electronic address:

Background & Aims: Flares after nucleos(t)ide analogue (NA) cessation are common and potentially harmful. Predictors of flares are required for risk stratification and to guide off-treatment follow-up.

Method: This multicenter cohort study included virally suppressed patients with chronic hepatitis B (CHB) who were hepatitis B e antigen negative at NA cessation.

View Article and Find Full Text PDF

Background & Aims: Alcohol-associated liver disease (ALD) burden has been rising globally, fueled by increases in high-risk alcohol use following the coronavirus disease 2019 (COVID-19) pandemic. We evaluated trends in annual incidence of alcohol-associated hepatitis (AH) before and following the onset of the COVID-19 pandemic across two geographically distinct populations in the USA and Hong Kong.

Methods: Using US national Veterans Affairs (VA) data and Hong Kong territory-wide data, trends in annual incidence of AH were evaluated from 2000 to 2023.

View Article and Find Full Text PDF

Progress towards hepatitis B virus (HBV) global elimination has been slow and most countries are far to reach the elimination targets set up by the World Health Organization (WHO). The burden of chronic hepatitis B is mainly bear by resource-limited countries where only a minority of people living with HBV are diagnosed and treated and international guidelines hardly applicable in real-life. In March 2024, the WHO released its revised guidelines for the prevention and management of chronic hepatitis B.

View Article and Find Full Text PDF

Reply to: "Insights into fracture risk with tenofovir and entecavir: Evidence from pharmacovigilance data".

J Hepatol

November 2024

Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address:

View Article and Find Full Text PDF

Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis.

J Hepatol

November 2024

Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address:

Background & Aims: Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, and treatment of patients at high risk of adverse outcomes. Clinical outcomes and the effect of antiviral therapy on the indeterminate phase remain unclear. We performed a systematic review and meta-analysis to study the incidence of adverse clinical outcomes including hepatocellular carcinoma (HCC), cirrhosis, and hepatic decompensation, and the effect of antiviral therapy, in the indeterminate phase.

View Article and Find Full Text PDF
Article Synopsis
  • The year 2024 marks the release of new clinical practice and management guidelines for chronic hepatitis B virus (HBV) infection, led by the World Health Organization (WHO) in March.
  • Key international liver disease societies, like the AASLD and EASL, are also updating their HBV guidelines but have not yet published them.
  • The chapter discusses recent developments, particularly focusing on the stringent Chinese guidelines from 2022 that recommend starting antiviral treatment at higher HBV DNA levels, examining the pros and cons of lowering treatment thresholds to prevent complications like hepatocellular carcinoma (HCC).
View Article and Find Full Text PDF

Why and when could nucleos(t)ide analogues treatment be withdrawn?

Dig Liver Dis

October 2024

Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital; Department of Clinical and Experimental Medicine, University of Pisa, Italy; Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy. Electronic address:

Article Synopsis
  • - Oral antiviral therapy with nucleos(t)ide analogues (NUCs) effectively reduces hepatitis B virus (HBV) levels, but achieving a functional cure (clearance of HBsAg) is uncommon.
  • - While stopping NUC treatment can lead to HBsAg loss in 10% to 20% of patients, there's a high risk of virological relapse (50% to 80%) and the need for retreatment (40% to 55%).
  • - Research is ongoing into using viral and immune biomarkers for better patient management post-treatment, along with AI-driven strategies for tailored NUC therapy decisions.
View Article and Find Full Text PDF

A New Predictive Algorithm toward Risk-Based Surveillance for Liver Cancer.

NEJM Evid

November 2024

State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong.

View Article and Find Full Text PDF

Reply to: Correspondence on "Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B".

J Hepatol

October 2024

Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address:

View Article and Find Full Text PDF

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.

Clin Gastroenterol Hepatol

October 2024

MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China. Electronic address:

Article Synopsis
  • Scientists studied a health problem called MASH, which affects people's livers, and worked on two tests to help doctors tell if someone has it.
  • They looked at data from over 3,000 people to make sure their first test, called acMASH, worked well, and then created a new test called acFibroMASH to find more severe cases.
  • The new acFibroMASH test was better at predicting who might have future liver problems compared to another test, showing it's a useful tool for doctors to keep patients healthy.
View Article and Find Full Text PDF

MASLD: a disease in flux.

Nat Rev Gastroenterol Hepatol

November 2024

Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

View Article and Find Full Text PDF

Utility of multi-biomarker panel on discriminating disease activity in patients with psoriatic arthritis.

Int Immunopharmacol

December 2024

Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Electronic address:

Article Synopsis
  • The study looked at how certain protein levels in the blood relate to how active the disease is in patients with Psoriatic Arthritis (PsA).
  • Researchers tested 48 different protein markers in 176 patients to see which ones could help indicate disease activity levels.
  • They found that six specific proteins were really good at predicting high disease activity, and their testing method performed better than a common test currently used.
View Article and Find Full Text PDF

Enhanced liver fibrosis (ELF) score is a noninvasive assessment for liver fibrosis. We aimed to evaluate the performance of changes in ELF score 3 years apart in combination with liver stiffness measurement (LSM)-hepatocellular carcinoma (HCC) score to predict HCC in chronic hepatitis B (CHB) patients. This is a prospective cohort study.

View Article and Find Full Text PDF

A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B.

J Hepatol

August 2024

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea; Inocras Inc., San Diego, CA, USA. Electronic address:

Article Synopsis
  • * Researchers analyzed data from nearly 4,800 patients and found that their model, named PLAN-B-CURE, outperformed existing prediction models significantly in various metrics.
  • * The results indicate that the PLAN-B-CURE model can be utilized for personalized monitoring of patients post-HBsAg seroclearance, improving long-term health management.
View Article and Find Full Text PDF

Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study.

Clin Gastroenterol Hepatol

August 2024

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:

Background & Aims: Hepatocellular carcinoma (HCC) risk persists in patients with chronic hepatitis B (CHB) despite antiviral therapy. The relationship between pre-treatment baseline hepatitis B virus (HBV) viral load and HCC risk during antiviral treatment remains uncertain.

Methods: This multinational cohort study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in 20,826 noncirrhotic, hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients with baseline HBV DNA levels ≥2000 IU/mL (3.

View Article and Find Full Text PDF

Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B.

Clin Gastroenterol Hepatol

August 2024

Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research, Guangzhou, China; Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangzhou, China; Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangzhou, China; Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangzhou, China. Electronic address:

Article Synopsis
  • The study focuses on predicting the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B receiving nucleos(t)ide analogues (NAs), emphasizing the importance of serum hepatitis B virus (HBV) RNA as a novel biomarker.
  • Researchers analyzed data from 1,374 NA-treated patients, tracking HBV RNA levels over three years and using a Cox proportional-hazard model to assess the link between HBV RNA declines and HCC risk, finding significant associations.
  • The findings suggest that patients with lower declines in HBV RNA at one and two years have a higher risk of developing HCC, and incorporating these declines into existing risk prediction models can improve their accuracy and help guide patient monitoring strategies
View Article and Find Full Text PDF

Introduction: The risk of ischemic stroke and intracerebral hemorrhage (ICH) with intensive lipid control by statins among patients with atrial fibrillation (AF) who require direct oral anticoagulants (DOAC) is unclear. We aimed to determine the risks of ischemic stroke and ICH in AF patients treated with DOAC and statins.

Patients And Methods: In a population-based retrospective cohort study, we identified AF patients concurrently on DOAC and statins from 2015 to 2021 in Hong Kong.

View Article and Find Full Text PDF
Article Synopsis
  • Statins provide multiple benefits for patients with metabolic-associated steatotic liver disease (MASLD), particularly in reducing long-term risks of all-cause mortality and liver-related clinical events (LREs).
  • A study followed 7988 patients for nearly 4.6 years, revealing that statin users had significantly lower risks of mortality (HR=0.233) and LREs (HR=0.380), as well as slower liver stiffness progression rates.
  • While statin usage is linked to a decrease in the progression of liver stiffness, it did not significantly correlate with liver stiffness regression, suggesting a complex relationship in liver health management.
View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) recurrence following surgical resection remains a significant clinical challenge, necessitating reliable predictive models to guide personalised interventions. In this study, we sought to harness the power of artificial intelligence (AI) to develop a robust predictive model for HCC recurrence using comprehensive clinical datasets.

Methods: Leveraging data from 958 patients across multiple centres in Australia and Hong Kong, we employed a multilayer perceptron (MLP) as the optimal classifier for model generation.

View Article and Find Full Text PDF

Background And Aims: Mother-to-child-transmission (MTCT) of hepatitis B virus (HBV) may still occur despite birth-dose HBV vaccinations when pregnant women are positive for hepatitis B surface antigen (HBsAg) with high viral loads (HBV DNA ≥ 200 000 IU/mL). A pilot integrated model nurse clinic (IMNC) was started in 2020 to implement the pre-emptive antiviral therapy with tenofovir disoproxil fumarate (TDF). We aimed to evaluate the performance of IMNC on uptake of TDF.

View Article and Find Full Text PDF